Healthcare
Statera Biopharma, Inc.(STAB)
Live Price
Offline$0.0001
+0.00% today
1Y Change
+0.00%
Window
Jun 20, 2025 โ Jun 12, 2026
- Market Cap
- โ
- Revenue Growth
- 0.0%
- EPS Growth
- -855.8%
- Dividend Yield
- 0.0%
Coverage: 246 bars ยท Jun 20, 2025 โ Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Statera Biopharma, Inc. (STAB) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and up 0.0% across the available one-year price window (Jun 20, 2025 โ Jun 12, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -855.8%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -855.8%, free cash flow -457.3% with operating margin 0.0% and ROIC -666.5%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines STAB price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2024 was reported on Jun 14, 2024, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at 0.0% and EPS is at -855.8%, with operating margin around 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged 0.0% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2024 Jun 14, 2024 | โ | +0.0% | +0.0% | +0.0% |
2024 May 17, 2024 | โ | +0.0% | +0.0% | +0.0% |
2024 Feb 12, 2024 | โ | +0.0% | +0.0% | +0.0% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
STAB
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
STAB Max Drawdown
-75.00%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for STAB and SPY.
Company Overview
Statera Biopharma, Inc.
Other OTC
Statera BioPharma, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses, and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. The company is developing therapies designed to directly elicit within patients a response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers. It has clinical programs for Crohn's disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401), and COVID-19 (STAT-205), as well as expanding into fibromyalgia and multiple sclerosis. The company was formerly known as Cytocom, Inc. and changed its name to Statera Biopharma, Inc. in September 2021. The company is based in Fort Collins, Colorado.
- Leadership
- Blake Hawley
- IPO Date
- Jul 28, 2021
- Employees
- 46
- Street Address
- 2537 Research Boulevard
- Mailing
- Fort Collins, CO, 80526
- Region
- Fort Collins, CO, US
- Reporting Currency
- USD
- Investor Line
- 888 613 8802
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- โ
Growth
- Revenue
- 0.0%
- EPS
- -855.8%
- Free Cash Flow
- -457.3%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- 6677.5%
- ROIC
- -666.5%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 0.37
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.